The following slide details the performance of this blood-based screening test: Perhaps most notably, Exact Sciences introduced Cancerguard™, a multi-cancer screening test that can detect multiple ...

Exact Sciences (NASDAQ: EXAS) CEO Kevin Conroy stood in front of the audience at the annual J.P. Morgan Healthcare Conference on Tuesday with good reason for confidence. After all, sales are booming ...

Exact Sciences reported total revenue of $707 million for Q1 2025, representing 11% year-over-year growth. The company’s core business segments both delivered positive results, with Screening revenue ...

Introduction & Market Context Exact Sciences Corporation (NASDAQ: EXAS) presented its second-quarter 2025 earnings on August 6, showcasing strong revenue growth and improved profitability that ...